Skip to main content

CASE REPORT article

Front. Endocrinol.
Sec. Pediatric Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1459451
This article is part of the Research Topic Metabolic Associated Fatty Liver Disease (MAFLD) in childhood: a new challenge View all 6 articles

Case report: Pediatric hepatopulmonary syndrome despite strict weight control after craniopharyngioma surgery

Provisionally accepted
Satoko Yoshikawa Satoko Yoshikawa 1Tomozumi Takatani Tomozumi Takatani 1*Rieko Takatani Rieko Takatani 1Ayano Inui Ayano Inui 2Tomoo Fujisawa Tomoo Fujisawa 2Hiromichi Hamada Hiromichi Hamada 1
  • 1 Chiba University, Chiba, Japan
  • 2 Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan

The final, formatted version of the article will be published soon.

    Childhood-onset craniopharyngiomas, though rare, are intracranial malformations that can cause obesity by disrupting the hypothalamus, a condition that often persists even after tumor resection.This severe obesity increases the risk of diabetes and fatty liver disease in childhood. Concurrently, panhypopituitarism, including growth hormone (GH) deficiency, may develop. Notably, some individuals with GH deficiency may exhibit a normal growth rate, making GH therapy unnecessary for growth purposes. However, in these cases, GH therapy may still be beneficial in preventing the progression of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. Although weight management is traditionally considered the gold standard for preventing liver cirrhosis, its effectiveness can be limited by hypothalamic dysfunction and the difficulty of achieving successful weight control. Our case study highlights a patient with normal growth despite GH deficiency, who did not receive GH replacement therapy and continued to struggle with hypothalamic obesity.Despite effective body weight control, the patient developed hepatopulmonary syndrome, indicating that relying solely on weight management may not be sufficient to prevent liver complications. This case underscores the importance of addressing GH deficiency even when growth is normal. Our findings suggest that GH replacement therapy could be beneficial for preventing liver cirrhosis in such cases.

    Keywords: Hepatopulmonary Syndrome, nonalcoholic steatohepatitis, Craniopharyngioma, Growth Hormone, obesity GH: growth hormone IGF-1: Insulin-like growth factor 1 HPS: Hepatopulmonary syndrome NAFLD: Nonalcoholic fatty liver disease

    Received: 04 Jul 2024; Accepted: 02 Oct 2024.

    Copyright: © 2024 Yoshikawa, Takatani, Takatani, Inui, Fujisawa and Hamada. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Tomozumi Takatani, Chiba University, Chiba, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.